Gene Therapy for CNS Diseases Using Intrabodies

Gene Therapy of the Central Nervous System: From Bench to Bedside

Volumn , Issue , 2006, Pages 133-149

  Miller, Todd W ^a   Messer, Anne ^b  

^a The Biologies Consulting Group   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84860664484     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012397632-1/50012-5     Document Type: Chapter

References (147)

1. Ackerley S., Grierson A.J., Banner S., Perkinton M.S., Brownlees J., Byers H.L., Ward M., Thornhill P., Hussain K., Waby J.S., Anderton B.H., Cooper J.D., Dingwall C., Leigh P.N., Shaw C.E., Miller C.C. p38alpha stress-activated protein kinase phosphorylates neurofilaments and is associated with neurofilament pathology in amyotrophic lateral sclerosis. Mol. Cell. Neurosci. 2004, 26:354-364.
2. Agar J., Durham H. Relevance of oxidative injury in the pathogenesis of motor neuron diseases. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 2003, 4:232-242.
3. Agrawal N., Pallos J., Slepko N., Apostol B.L., Bodai L., Chang L.W., Chiang A.S., Thompson L.M., Marsh J.L. Identification of combinatorial drug regimens for treatment of Huntington's disease using Drosophila. Proc. Natl. Acad. Sci. USA 2005, 102:3777-3781.
4. Alvarez R.D., Barnes M.N., Gomez-Navarro J., Wang M., Strong T.V., Arafat W., Arani R.B., Johnson M.R., Roberts B.L., Siegal G.P., Curiel D.T. A cancer gene therapy approach utilizing an anti-erbB-2-single-chain antibody-encoding adenovirus (AD21): a phase I trial. Clin. Cancer Res. 2000, 6:3081-3087.
5. Barrow C.J., Zagorski M.G. Solution structures of beta peptide and its constituent fragments: relation to amyloid deposition. Science 1991, 253:179-182.
6. Bates G. Huntington aggregation and toxicity in Huntington's disease. Lancet 2003, 361:1642-1644.
7. Beyer W.E., Palache A.M., Luchters G., Nauta J., Osterhaus A.D. Seroprotection rate mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination?. Virus Res. 2004, 103:125-132.
8. Bird R.E., Hardman K.D., Jacobson J.W., Johnson S., Kaufman B.M., Lee S.M., Lee T., Pope S.H., Riordan G.S., Whitlow M. Single-chain antigen-binding proteins [erratum appears in Science, 1989 Apr 28;244(4903):409]. Science 1988, 242:423-426.
9. Boder E.T., Wittrup K.D. Yeast surface display for screening combinatorial polypeptide libraries. Nat. Biotechnol. 1997, 15:553-557.
10. Bodles A.M., Guthrie D.J., Greer B., Irvine G.B. Identification of the region of non-Abeta component (NAC) of Alzheimer's disease amyloid responsible for its aggregation and toxicity. J. Neurochem. 2001, 78:384-395.
11. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991, 82:239-259.
12. Brown D.R. Role of the prion protein in copper turnover in astrocytes. Neurobiol. Dis. 2004, 15:534-543.
13. Bruijn L.I., Becher M.W., Lee M.K., Anderson K.L., Jenkins N.A., Copeland N.G., Sisodia S.S., Rothstein J.D., Borchelt D.R., Price D.L., Cleveland D.W. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 1997, 18:327-338.
14. Bruijn L.I., Houseweart M.K., Kato S., Anderson K.L., Anderson S.D., Ohama E., Reaume A.G., Scott R.W., Cleveland D.W. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 1998, 281:1851-1854.
15. Busciglio J., Gabuzda D.H., Matsudaira P., Yankner B.A. Generation of beta-amyloid in the secretory pathway in neuronal and nonneuronal cells. Proc. Natl. Acad. Sci. USA. 1993, 90:2092-2096.
16. sc accumulation. J. Biol. Chem. 2005, 280:685-694.
17. Castilla J., Hetz C., Soto C. Molecular mechanisms of neurotoxicity of pathological prion protein. Curr. Mol. Med. 2004, 4:397-403.
18. Caughey B.W., Dong A., Bhat K.S., Ernst D., Hayes S.F., Caughey W.S. Secondary structure analysis of the scrapie-associated protein PrP 27-30 in water by infrared spectroscopy[erratum appears in Biochemistry, 1991 Oct 29; 30(43): 10600]. Biochemistry 1991, 30:7672-7680.
19. Citron M. Strategies for disease modification in Alzheimer's disease. Nat. Rev. Neurosci. 2004, 5:677-685.
20. Colby D.W., Chu Y., Cassady J.P., Duennwald M., Zazulak H., Webster J.M., Messer A., Lindquist S., Ingram V.M., Wittrup K.D. Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody. Proc. Natl. Acad. Sci. 2004, 101:17616-17621.
21. Colby D.W., Garg P., Holden T., Chao G., Webster J.M., Messer A., Ingram V.M., Wittrup K.D. Development of a human light chain variable domain (V(L)) intracellular antibody specific for the amino terminus of hungtingtin via yeast surface display. J. Mol. Biol. 2004, 342:901-912.
22. Colby D.W., Kellogg B.A., GraffC.P., Yeung Y.A., Swers J.S., Wittrup K.D. Engineering antibody affinity by yeast surface display. Method. Enzymol. 2004, 388:348-358.
23. Conway K.A., Harper J.D., Lansbury P.T. Accelerated in vitro formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat. Med. 1998, 4:1318-1320.
24. Crowther R.A., Goedert M. Abnormal tau-containing filaments in neurodegenerative disease. J. Struct. Biol. 2000, 130:271-279.
25. Dawson T.M., Dawson V.L. Molecular pathways of neurodegeneration in Parkinson's disease. Science 2003, 302:819-822.
26. Dietz G.P., Bahr M. Delivery of bioactive molecules into the cell: the Trojan horse approach. Mol. Cell. Neurosci. 2004, 27:85-131.
27. Drewes G. MARKing tau for tangles and toxicity. Trends Biochem. Sci. 2004, 29:548-555.
28. Duda J.E., Giasson B.I., Chen Q., Gur T.L., Hurtig H.L., Stern M.B., Gollomp S.M., Ischiropoulos H., Lee V.M., Trojanowski J.Q. Widespread nitration of pathological inclusions in neurodegenerative synucleinopatheis. Am. J. Pathol. 2000, 157:1439-1445.
29. El-Agnaf O.M., Jakes R., Curran M.D., Middleton D., Ingenito R., Bianchi E., Pessi A., Neill D., Wallace A. Aggregates from mutant and wild-type alpha-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of beta-sheet and amyloid-like filaments. FEBS Lett. 1998, 440:71-75.
30. El-Agnaf O.M., Paleologou K.E., Greer B., Abogrein A.M., King J.E., Salem S.A., Fullwood N.J., Benson F.E., Hewitt R., Ford K.J., Martin F.L., Harriott P., Cookson M.R., Allsop D. A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders. FASEB J 2004, 18:1315-1317.
31. Elam J.S., Taylor A.B., Strange R., Antonyuk S., Doucette P.A., Rodriguez J.A., Hasnain S.S., Hayward L.J., Valentine J.S., Yeates T.O., Hart P.J. Amyloid-like filaments and water-filled nanotubes formed by SOD1 mutant proteins linked to familial ALS. Nat. Struct Biol. 2003, 10:461-467.
32. Emadi S., Liu R., Yuan B., Schulz P., McAllister C., Lyubchenko Y., Messer A., Sierks M.R. Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments. Biochemistry 2004, 43:2871-2878.
33. Emamian E.S., Kaytor M.D., Duvick L.A., Zu T., Tousey S.K., Zoghbi H.Y., Clark H.B., Orr H.T. Serine 776 of ataxin-1 is critical for polyglutamine-induced disease in SCA1 transgenic mice. Neuron 2003, 38:375-387.
34. Ewert S., Honegger A., Pluckthun A. Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering. Methods 2004, 34:184-199.
35. Fridovich I. Superoxide dismutases. Adv. Enzymol. Relat. Areas Mol. Biol. 1986, 58:61-97.
36. Fujiwara H., Hasegawa M., Dohmae N., Kawashima A., Masliah E., Goldberg M.S., Shen J., Takio K., Iwatsubo T. Alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 2002, 4:160-164.
37. Gennari F., Mehta S., Wang Y., St Clair Tallarico A., Palu G., Marasco W.A. Direct phage to intrabody screening (DPIS): demonstration by isolation of cytosolic intrabodies against the TES1 site of Epstein Barr virus latent membrane protein 1 (LMP1) that block NF-kappaB transactivation. J. Mol. Biol. 2004, 335:193-207.
38. Geschwind D.H. Tau phosphorylation, tangles, and neurodegeneration: the chicken or the egg?. Neuron 2003, 40:457-460.
39. Giasson B.I., Duda J.E., Murray I.V., Chen Q., Souza J.M., Hurtig H.I., Ischiropoulos H., Trojanowski J.Q., Lee V.M. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions.[see comment]. Science 2000, 290:985-989.
40. Giasson B.I., Lee V.M. Are ubiquitination pathways central to Parkinson's disease?. Cell 2003, 114:1-8.
41. Glabe C.G. Conformation-dependent antibodies target diseases of protein misfolding. Trends Biochem. Sci. 2004, 29:542-547.
42. Glenner G.G., Wong C.W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 1984, 120:885-890.
43. Goldgaber D., Lerman M.I., McBride W.O., Saffiotti U., Gajdusek D.C. Isolation, characterization, and chromosomal localization of human brain cDNA clones coding for the precursor of the amyloid of brain in Alzheimer's disease, Down's syndrome and aging. J. Neural Transm. Suppl. 1987, 24:23-28.
44. Haass C., Hung A.Y., Schlossmacher M.G., Oltersdorf T., Teplow D.B., Selkoe D.J. Normal cellular processing of the beta-amyloid precursor protein results in the secretion of the amyloid beta peptide and related molecules. Ann. NY Acad. Sci. 1993, 695:109-116.
45. Han H., Weinreb P.H., Lansbury P.T. The core Alzheimer's peptide NAC forms amyloid fibrils which seed and are seeded by beta-amyloid: is NAC a common trigger or target in neurodegenerative disease?. Chem. Biol. 1995, 2:163-169.
46. Harada A., Oguchi K., Okabe S., Kuno J., Terada S., Ohshima T., Sato-Yoshitake R., Takei Y., Noda T., Hirokawa N. Altered microtubule organization in small-calibre axons of mice lacking tau protein. Nature 1994, 369:488-491.
47. Harper S.Q., Staber P.D., He X., Eliason S.L., Martins I.H., Mao Q., Yang L., Kotin R.M., Paulson H.L., Davidson B.L. From the cover: RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc. Natl. Acad. Sci. USA 2005, 102:5820-5825.
48. Hasegawa M., Fujiwara H., Nonaka T., Wakabayashi K., Takahashi H., Lee V.M., Trojanowski J.Q., Mann D., Iwatsubo T. Phosphorylated alpha-synuclein is ubiquitinated in alphasynucleinopathy lesions. J. Biol. Chem. 2002, 277:49071-49076.
49. Heppner F.L., Musahl C., Arrighi I., Klein M.A., Rulicke T., Oesch B., Zinkernagel R.M., Kalinke U., Aguzzi A. Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science 2001, 294:178-182.
50. Hersch S.M., Ferrante R.J. Translating therapies for Huntington's disease from genetic animal models to clinical trials. Neurorx 2004, 1:298-306.
51. Hong S., Kim S.J., Ka S., Choi I., Kang S. USP7, a ubiquitin-specific protease, interacts with ataxin-1, the SCA1 gene product. Mol. Cell. Neurosci. 2002, 20:298-306.
52. Horiguchi T., Uryu K., Giasson B.I., Ischiropoulos H., LightFoot R., Bellmann C., Richter-Landsberg C., Lee V.M., Trojanowski J.Q. Nitration of tau protein is linked to neurodegeneration in tauopathies [erratum appears in Am J Pathol, 2003 Dec; 163(6): 2645]. Am. J. Pathol. 2003, 163:1021-1031.
53. Huston J.S., Levinson D., Mudgett-Hunter M., Tai M.S., Novotny J., Margolies M.N., Ridge R.J., Bruccoleri R.E., Haber E., Crea R. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc. Natl. Acad. Sci. USA 1988, 85:5879-5883.
54. Ischiropoulos H. Oxidative modifications of alpha-synuclein. Ann. NY Acad. Sci. 2003, 991:93-100.
55. Jeffrey M., Goodsir C.M., Race R.E., Chesebro B. Scrapie-specific neuronal lesions are independent of neuronal PrP expression. Ann. Neurol. 2004, 55:781-792.
56. Kahle P.J., Neumann M., Ozmen L., Muller V., Jacobsen H., Spooren W., Fuss B., Mallon B., Macklin W.B., Fujiwara H., Hasegawa M., Iwatsubo T., Kretzschmar H.A., Haass C. Hyperphosphorylation and insolubility of alpha-synuclein, in transgenic mouse oligodendrocytes. EMBO Rep. 2002, 3:583-588.
57. Kang J., Lemaire H.G., Unterbeck A., Salbaum J.M., Masters C.L., Grzeschik K.H., Multhaup G., Beyreuther K., Muller-Hill B. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987, 325:733-736.
58. Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W., Glabe C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003, 300:486-489.
59. Kazantsev A., Walker H.A., Slepko N., Bear J.E., Preisinger E., Steffan J.S., Zhu Y.Z., Gertler F.B., Housman D.E., Marsh J.L., Thompson L.M. A bivalent Huntingtin binding peptide, suppresses polyglutamine aggregation and pathogenesis in Drosophila. Nat. Genet. 2002, 30:367-376.
60. Khoshnan A., Ko J., Patterson P.H. Effects of intracellular expression of anti-huntingtin, antibodies of various specificities on mutant huntingtin aggregation and toxicity. Proc. Natl. Acad. Sci. USA. 2002, 99:1002-1007.
61. Kieke M.C., Cho B.K., Boder E.T., Kranz D.M., Wittrup K.D. Isolation of anti-T cell receptor scFv mutants by yeast surface display. Protein Eng. 1997, 10:1303-1310.
62. Kim M., Lee H.S., LaForet G., McIntyre C., Martin E.J., Chang P., Kim T.W., Williams M., Reddy P.H., Tagle D., Boyce F.M., Won L., Heller A., Aronin N., DiFiglia M. Mutant huntingtin expression in clonal striatal cells: dissociation of inclusion formation and neuronal survival by caspase inhibition. J. Neurosci. 1999, 19:964-973.
63. Kim Y.J., Yi Y., Sapp E., Wang Y., Cuiffo B., Kegel K.B., Qin Z.H., Aronin N., DiFiglia M. Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis. Proc. Natl. Acad. Sci. USA 2001, 98:12784-12789.
64. Kitamoto J., Muramoto T., Mohri S., Doh-Ura K., Tateishi J. Abnormal isoform of prion protein accumulates in follicular dendritic cells in mice with Creutzfeldt-Jakob disease. J. Virol. 1991, 65:6292-6295.
65. Konig G., Monning U., Czech C., Prior R., Banati R., Schreiter-Gasser U., Bauer J., Masters C.L., Beyreuther K. Identification and diffential expression of a novel alternative splice isoform of the beta A4 amyloid precursor protein (APP) mRNA in leukocytes and brain microglial cells. J. Biol. Chem. 1992, 267:10804-10809.
66. Leath C.A., Douglas J.T., Curiel D.T., Alvarez R.D. Single-chain antibodies: a therapeutic modality for cancer gene therapy (review). Int. J. Oncol 2004, 24:765-771.
67. Lecerf J.M., Shirley T.L., Zhu Q., Kazantsev A., Amersdorfer P., Housman D.E., Messer A., Huston J.S. Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease. Proc. Natl. Acad. Sci. USA 2001, 98:4764-4769.
68. Leclerc E., Liemann S., Wildegger G., Vetter S.W., Nilsson F. Selection and characterization of single chain Fv fragments against murine recombinant prion protein from a synthetic human antibody phage display library. Hum. Antibodies 2000, 9:207-214.
69. Lee M.K., Stirling W., Xu Y., Xu X., Qui D., Mandir A.S., Dawson T.M., Copeland N.G., Jenkins N.A., Price D.L. Human alpha-synuclein-harboring familial Parkinson's disease with alpha-synuclein aggregation in transgenic mice. Proc. Natl. Acad. Sci. USA 2002, 99:896-897.
70. Lee V.M., Giasson B.I., Trojanowski J.Q. More than just two peas in a pod: common amyloidogenic properties of tau and alpha-synuclein in neurodegenerative diseases. Trends neurosci 2004, 27:129-134.
71. Lee V.M., Goedert M., Trojanowski J.Q. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 2001, 24:1121-1159.
72. Lewis J., McGowan E., Rockwood J., Melrose H., Nacharaju P., Van Slegtenhorst M., Gwinn-Hardy K., Paul Murphy M., Baker M., Yu X., DuffK., Hardy J., Corral A., Lin W.L., Yen S.H., Dickson D.W., Davies P., Hutton M. Neurofibrillary tangles amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet. 2000, 25:402-405.
73. Li W., West N., Colla E., Pletnikova O., Troncoso J.C., Marsh L., Dawson T.M., Jakala P., Hartmann T., Price D.L., Lee M.K. Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc. Natl. Acad. Sci. 2005, 102:2162-2167.
74. Liu C.W., Giasson B.I., Lewis K.A., Lee V.M., Demartino G.N., Thomas P.J. A precipitating role for truncated alphasynuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson's disease. J. Biol. Chem. 2005, 280:22670-22678.
75. Liu R., McAllister C., Lyubchenko Y., Sierks M.R. Proteolytic antibody light chains alter beta-amyloid aggregation and prevent cytotoxicity. Biochemistry 2004, 43:9999-10007.
76. Liu R., Yuan B., Emadi S., Zameer A., Schulz P., McAllister C., Lyubchenko Y., Goud G., Sierks M.R. Single chain variable fragments against beta-amyloid (Abeta) can inhibit Abeta aggregation and prevent abeta-induced neurotoxicity. Biochemistry 2004, 43:6959-6967.
77. Lorenzo A., Yankner B.A. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc. Natl. Acad. Sci. USA 1994, 91:12243-12247.
78. Luhr K.M., Nordstrom E.K., Low P., Ljunggren H.G., Taraboulos A., Kristensson K. Scrapie protein degradation by cysteine proteases in CD11c+ dendritic cells and GT1-1 neuronal cells. J. Virol. 2004, 78:4776-4782.
79. sc-like conformation in the cytosol. [see comment]. Science 2002, 298:1785-1788.
80. Ma J., Wollmann R., Lindquist S. Neurotoxicity and neurodegeneration when PrP accumulates in the cytosol. [see comment]. Science 2002, 298:1781-1785.
81. Maguire-Zeiss K.A., FederoffH.J. Convergent pathobiologic model of Parkinson's disease. Ann. NY Acad. Sci. 2003, 991:152-166.
82. Maguire-Zeiss K.A., Yehling E., Giuliano R., Sullivan M., FederoffH.J. HSV amplicon expression of single-chain antibodies directed against alpha-synuclein conformers. Mol. Ther. 2004, 9:S86.
83. Manoutcharian K., Acero G., Munguia M.E., Becerril B., Massieu L., Govezensky T., Ortiz E., Marks J.D., Cao C., Ugen K., Gevorkian G. Human single chain Fv antibodies and a complementarity determining region-derived peptide binding to amyloid-beta 1-42. Neurobiol. Dis. 2004, 17:114-121.
84. Marasco W.A., LaVecchio J., Winkler A. Human anti-HIV-1 tat sFv intrabodies for gene therapy of advanced HIV-1-infection and AIDS. J. Immunol. Methods 1999, 231:223-238.
85. Marks J.D., Hoogenboom H.R., Bonnert T.P., McCafferty J., Griffiths A.D., Winter G. By-passing immunization: human antibodies from V-gene libraries displayed on phage. J. Mol. Biol. 1991, 222:581-597.
86. Marsh J.L., Thompson L.M. Can flies help humans treat neurodegenerative diseases?. Bioessays 2004, 26:485-496.
87. Martin-Aparicio E., Yamamoto A., Hernandez F., Hen R., Avila J., Lucas J.J. Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington's disease. J. Neurosci. 2001, 21:8772-8781.
88. Martinov V.N., Sefland I., Walaas S.I., Lomo T., Nja A., Hoover F. Targeting functional subtypes of spinal motoneurons and skeletal muscle fibers in vivo by intramuscular injection of adenoviral and adeno-associated viral vectors. Anat. Embryol. (Berl.) 2002, 205:215-221.
89. Masters C.L., Simms G., Weinman N.A., Multhaup G., McDonald B.L., Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. 1985, 82:4245-4249.
90. Mazarakis N.D., Azzouz M., Rohll J.B., Ellard F.M., Wilkes F.J., Olsen A.L., Carter E.E., Barber R.D., Baban D.F., Kingsman S.M., Kingsman A.J., O'Malley K., Mitrophanous K.A. Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery. Hum. Mol. Genet. 2001, 10:2109-2121.
91. McNaught K.S., Perl D.P., Brownell A.L., Olanow C.W. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann. Neurol. 2004, 56:149-162.
92. Michalik A., Van Broeckhoven C. Pathogenesis of polyglutamine disorders: aggregation revisited. Hum. Mol. Genet. 2003, 12(Spec No 2):R173-R186.
93. Miller T.W., Messer A. Intrabody applications in neurological disorders: progress and future prospects. Mol. Ther. 2005, 12:394-401.
94. Miller T.W., Zhou C., Gines S., MacDonald M.E., Mazarakis N.D., Bates G.P., Messer A. A human single-chain Fv intrabody selectively targets amino-terminal huntingtin fragments in striatal models of Huntington's disease. Neurobiol. Dis. 2005, 19:47-56.
95. Mishizen-Eberz A.J., Guttmann R.P., Giasson B.I., Day G.A., Hodara R., Ischiropoulos H., Lee V.M., Trojanowski J.Q., Lynch D.R. Distinct cleavage patterns of normal and pathologic forms of alpha-synuclein by calpain I in vitro. J. Neurochem. 2003, 86:836-847.
96. Mitrophanous K., Yoon S., Rohll J., Patil D., Wilkes F., Kim V., Kingsman S., Kingsman A., Mazarakis N. Stable gene transfer to the nervous system using a non-primate lentiviral vector. Gene Ther. 1999, 6:1808-1818.
97. Mossner E., Koch H., Pluckthun A. Fast selection of antibodies without antigen purification: adaptation of the protein fragment complementation assay to select antigen-antibody pairs. J. Mol. Biol. 2001, 308:115-122.
98. Murphy R.C., Messer A. A single-chain Fv intrabody provides functional protection against the effects of mutant protein in an organotypic slice culture model of Huntington's disease. Brain Res. Mol. Brain Res. 2004, 121:141-145.
99. Nagai Y., Tucker T., Ren H., Kenan D.J., Henderson B.S., Keene J.D., Strittmatter W.J., Burke J.R. Inhibition of polyglutamine protein aggregation and cell death by novel peptides identified by phage display screening. J. Biol. Chem. 2000, 275:10437-10442.
100. Oliver C., Holland A.J. Down's syndrome and Alzheimer's disease: a review. Psychol. Med. 1986, 16:307-322.
101. Onodera O., Burke J.R., Miller S.E., Hester S., Tsuji S., Roses A.D., Strittmatter W.J. Oligomerization of expanded-polyglutamine domain fluorescent fusion proteins in cultured mammalian cells. Biochem. Biophys. Res. Commun. 1997, 238:599-605.
102. O'Nuallain B., Wetzel R. Conformational Abs recognizing a generic amyloid fibril epitope. Proc. Natl. Acad. Sci. USA 2002, 99:1485-1490.
103. Orlandi R., Gussow D.H., Jones P.T., Winter G. Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. Proc. Natl. Acad. Sci. USA 1989, 86:3833-3837.
104. Osbourn J.K., Field A., Wilton J., Derbyshire E., Earnshaw J.C., Jones P.T., Allen D., McCafferty J. Generation of a panel of related human scFv antibodies with high affinities for human CEA. Immunotechnology 1996, 2:181-196.
105. Paganetti P., Calanca V., Galli C., Stefani M., Molinari M. β-site specific intrabodies to decrease and prevent generation of Alzheimer's Aβ peptide. J. Cell Biol. 2005, 168:863-868.
106. Pan K.M., Baldwin M., Nguyen J., Gasset M., Serban A., Groth D., Mehlhorn I., Huang Z., Fletterick R.J., Cohen F.E. Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. Proc. Natl. Acad. Sci. USA 1993, 90:10962-10966.
107. Papay R., Zuscik M.J., Ross S.A., Yun J., McCune D.F., Gonzalez-Cabrera P., Gaivin R., Drazba J., Perez D.M. Mice expressing the alpha(1B)-adrenergic receptor induces a synucleinopathy with excessive tyrosine nitration but decreased phosphorylation. J. Neurochem. 2002, 83:623-634.
108. Pike C.J., Walencewicz A.J., Glabe C.G., Cotman C.W. In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res. 1991, 563:311-314.
109. Prusiner S.B. Novel proteinaceous infectious particles cause scrapie. Science 1982, 216:136-144.
110. Prusiner S.B. Molecular biology of prion diseases. Science 1991, 252:1515-1522.
111. Prusiner S.B. Prions. Proc. Natl. Acad. Sci. USA 1998, 95:13363-13383.
112. Rakhit R., Crow J.P., Lepock J.R., Kondejewski L.H., Cashman N.R., Chakrabartty A. Monomeric Cu, Zn-superoxide dismutase is a common misfolding intermediate in the oxidation models of sporadic and familial amyotrophic lateral sclerosis. J. Biol. Chem. 2004, 279:15499-15504.
113. Rangan S.K., Liu R., Brune D., Planque S., Paul S., Sierks M.R. Degradation of beta-amyloid by proteolytic antibody light chains. Biochemistry 2003, 42:14328-14334.
114. Ross C.A., Poirier M.A. Protein aggregation and neurodegenerative disease. Nat. Med. 2004, 10(Suppl):S10-S17.
115. Ross C.A., Poirier M.A., Wanker E.E., Amzel M. Polyglutamine fibrillogenesis: the pathway unfolds. Proc. Natl. Acad. Sci. USA 2003, 100:1-3.
116. Scherzinger E., Lurz R., Turmaine M., Mangiarini L., Hollenbach B., Hasenbank R., Bates G.P., Davies S.W., Lehrach H., Wanker E.E. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 1997, 90:549-558.
117. Schier R., Marks J.D. Efficient in vitro affinity maturation of phage antibodies using BIAcore guided selections. Hum. Antibodies Hybridomas 1993, 7:97-105.
118. Shoji M., Golde T.E., Ghiso J., Cheung T.T., Estus S., Shaffer L.M., Cai X.D., McKay D.M., Tintner R., Frangione B. Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science 1992, 258:126-129.
119. Souza J.M., Giasson B.I., Chen Q., Lee V.M., Ischiropoulos H. Dityrosine cross-linking promotes formation of stable alphasynuclein polymers; implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J. Biol. Chem. 2000, 275:18344-18349.
120. Stemmer W.P. DNA shuffling by random fragmentation and reassembly: in vitro recombination for molecular evolution. Proc. Natl. Acad. Sci. USA 1994, 91:10747-10751.
121. Stocks M.R. Intrabodies: production and promise. Drug Discov. Today 2004, 9:960-966.
122. Tagliavini F., Prelli F., Porro M., Rossi G., Giaccone G., Farlow M.R., Dlouhy S.R., Ghetti B., Bugiani O., Frangione B. Amyloid fibrils in Gerstmann-Straussler-Scheinker disease (Indiana and Swedish kindreds) express only PrP peptides encoded by the mutant allele. Cell 1994, 79:695-703.
123. Takahashi T., Yamashita H., Nakamura T., Nagano Y., Nakamura S. Tyrosine 125 of alpha-synuclein plays a critical role for dimerization following nitrative stress. Brain Res. 2002, 938:73-80.
124. Tanaka T., Chung G.T., Forster A., Lobato M.N., Rabbitts T.H. De novo production of diverse intracellular antibody libraries. Nucleic Acids Res. 2003, 31:E23.
125. Tarlac V., Storey E. Role of proteolysis in polyglutamine disorders. J. Neurosci. Res. 2003, 74:406-416.
126. Tewari D., Notkins A.L., Zhou P. Inhibition of HIV-1 replication in primary human T cells transduced with an intracellular anti-HIV-1 p17 antibody gene. J. Gene Med. 2003, 5:182-189.
127. Tse E., Lobato M.N., Forster A., Tanaka T., Chung G.T., Rabbitts T.H. Intracellular antibody capture technology: application to selection of intracellular antibodies recognising the BCR-ABL oncogenic protein. J. Mol. Biol. 2002, 317:85-94.
128. Ueda K., Fukushima H., Masliah E., Xia Y., Iwai A., Yoshimoto M., Otero D.A., Kondo J., Ihara Y., Saitoh T. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. USA 1993, 90:11282-11286.
129. Uversky V.N., Fink A.L. Amino acid determinants of alpha-synuclein aggregation: putting together pieces of the puzzle. FEBS Lett. 2002, 522:9-13.
130. Vila M., Przedborski S. Genetic clues to the pathogenesis of Parkinson's disease. Nat. Med. 2004, 10(Suppl):S58-S62.
131. Visintin M., Settanni G., Maritan A., Graziosi S., Marks J.D., Cattaneo A. The intracellular antibody capture technology (IACT): towards a consensus sequence for intracellular antibodies. J. Mol. Biol. 2002, 317:73-83.
132. Volles M.J., Lansbury P.T. Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease. Biochemistry 2003, 42:7871-7878.
133. Weissmann C., Flechsig E. PrP knock-out and PrP transgenic mice in prion research. Brit. Med. Bull. 2003, 66:43-60.
134. Wellington C.L., Singaraja R., Ellerby L., Savill J., Roy S., Leavitt B., Cattaneo E., Hackam A., Sharp A., Thornberry N., Nicholson D.W., Bredesen D.E., Hayden M.R. Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells. J. Biol. Chem. 2000, 275:19831-19838.
135. Wheeler Y.Y., Chen S.Y., Sane D.C. Intrabody and intrakine strategies for molecular therapy. Mol. Ther. 2003, 8:355-366.
136. Wheeler Y.Y., Kute T.E., Willingham M.C., Chen S.Y., Sane D.C. Intrabody-based strategies for inhibition of vascular endothelial growth factor receptor-2: effects on apoptosis, cell growth, and angiogenesis. FASEB J. 2003, 17:1733-1735.
137. Wisniewski K.E., Wisniewski H.M., Wen G.Y. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann. Neurol. 1985, 17:278-282.
138. Worn A., Auf der Maur A., Escher D., Honegger A., Barberis A., Pluckthun A. Correlation between in vitro stability and in vivo performance of anti-GCN4 intrabodies as cytoplasmic inhibitors. J. Biol. Chem. 2000, 275:2795-2803.
139. Wuertzer C.A., Sullivan M., FederoffH.J. Single-chain antibodies for viral-based passive immuno-therapy for prion disease: linear epitope mapping and clearance from thalamic injection. Mol. Ther. 2004, 9:S208.
140. Xia H., Mao Q., Eliason S.L., Harper S.Q., Martins I.H., Orr H.T., Paulson H.L., Yang L., Kotin R.M., Davidson B.L. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat. Med. 2004, 10:816-820.
141. Yamamoto A., Lucas J.J., Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease.[see comment]. Cell 2000, 101:57-66.
142. Yoshimoto M., Iwai A., Kang D., Otero D.A., Xia Y., Saitoh T. NACP, the precursor protein of the non-amyloid beta/A4 protein (Abeta) component of Alzheimer disease amyloid, binds Abeta and stimulates Abeta aggregation. Proc. Natl. Acad. Sci. USA 1995, 92:9141-9145.
143. Zhang J.Y., Liu S.J., Li H.L., Wang J.Z. Microtubule-associated protein tau is a substrate of ATP/Mg(2+)-dependent proteasome protease system. J. Neural Transm. 2004, 112:547-555.
144. Zhang X., Smith D.L., Meriin A.B., Engemann S., Russel D.E., Roark M., Washington S.L., Maxwell M.M., Marsh J.L., Thompson L.M., Wanker E.E., Young A.B., Housman D.E., Bates G.P., Sherman M.Y., Kazantsev A.G. A pontent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo. Proc. Natl. Acad. Sci. USA 2005, 102:892-897.
145. Zhou C., Emadi S., Sierks M.R., Messer A. A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed a-synuclein. Mol. Ther. 2004, 10:1023-1031.
146. Zhou Y., Shie F.S., Piccardo P., Montine T.J., Zhang J. Proteasomal inhibition induced by manganese ethylene-bisdithiocarbamate: relevance to Parkinson's disease. Neuroscience 2004, 128:281-291.
147. Zhu Q., Zeng C., Huhalov A., Yao J., Turi T.G., Danley D., Hynes T., Cong Y., DiMattia D., Kennedy S., Daumy G., Schaeffer E., Marasco W.A., Huston J.S. Extended half-life and elevated steady-state level of a single-chain Fv intrabody are critical for specific intracellular retargeting of its antigen, caspase-7. J. Immunol. Methods 1999, 231:207-222.